Edgewise Therapeutics logo

Edgewise Therapeutics

EWTX | NASDAQ
Chart Builder DCF Calculator
$43.68
-$2.25 (-4.90%)
At close: Nov 16, 2026, 4:00 PM ET
$43.68
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
-4.90%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
40.6
-1.0 pts
Fundamentals Average
Market Sentiment Bullish
Moat None
Sector Rank #507/1021 (Top 50%)

Key Statistics

Market Data

Market Cap $4.7B
1D Range
43.44 46.00
52W Range
20.94 48.74

Valuation (TTM)

PE 5.33
PB 2.88
EV/EBITDA 2.54

Valuation (NTM)

Forward PE 5.11
Forward PEG -0.01
Price Target $52.00
Loading financial charts...

Profile

Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an or...

Sector Healthcare
Industry Biotechnology
Employees 127
IPO Date Mar 26, 2021
Fiscal Year January - December

Latest News

Edgewise Therapeutics to Participate in Upcoming Investor Conferences

8 days ago · prnewswire.com

Edgewise Therapeutics to Participate in Upcoming Investor Conferences
Edgewise Therapeutics Reports Third Quarter 2026 Financial Results

12 days ago · prnewswire.com

Edgewise Therapeutics Reports Third Quarter 2026 Financial Results
Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400

1 month ago · prnewswire.com

Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400

2 months ago · seekingalpha.com

Edgewise Therapeutics, Inc. (EWTX) Discusses Differentiated Mechanism of Action of Cardiac Sarcomere Modulator EDG-7500 Transcript

2 months ago · prnewswire.com

Edgewise Therapeutics Unveils the Differentiated Mechanism of Action (MoA) of its Cardiac Sarcomere Modulator EDG-7500
Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026

3 months ago · prnewswire.com

Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026
Edgewise Therapeutics: The Servier Deal Creates A Self-Funded Cardiovascular Platform

3 months ago · seekingalpha.com

Edgewise Therapeutics: The Servier Deal Creates A Self-Funded Cardiovascular Platform
Edgewise Therapeutics Reports Second Quarter 2026 Financial Results

3 months ago · prnewswire.com

Edgewise Therapeutics Reports Second Quarter 2026 Financial Results
Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline

4 months ago · prnewswire.com

Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline
Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy Transcript

5 months ago · seekingalpha.com

Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy Transcript

Earnings

Next Earnings
Feb 25, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
7
Consensus
Buy
Price Target
$52.00
Upside
+19.05%
Buy (6)
Hold (1)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.